News >

PFS Benefit Confirmed With Daratumumab Plus VMP in Newly Diagnosed Myeloma

Shannon Connelly
Published: Monday, Jan 21, 2019

Maria-Victoria Mateos, MD, PhD

Maria-Victoria Mateos, MD, PhD
Daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) continued to significantly improve progression-free survival (PFS) in patients with newly diagnosed multiple myeloma, according to updated findings of the phase III ALCYONE study.

during the 2018 ASH Annual Meeting, Mateos discussed the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

OncLive: Can you give some background on this study?

Mateos: Multiple myeloma usually affects the elderly population. In fact, it's the second most frequent hematologic malignancy. Most patients with multiple myeloma are not eligible for autologous stem cell transplantation. Bortezomib plus melphalan and prednisone has been a standard of care that we have used for this population for many years. Daratumumab is an anti-CD38 monoclonal antibody that has shown to be very effective as a single agent and in combination with either bortezomib or lenalidomide in relapsed and refractory myeloma patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x